Adcytherix
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).
Adcytherix has raised $122M across 1 round. Its most recent round was a Series A of $122M in Oct 2025. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Adcytherix is featured in
Similar companies
Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research.
Dayra Therapeutics manufactures peptide based medicines.
4TEEN4 Pharmaceuticals develops innovative therapies and biomarkers for diagnosis, prediction, and treatment of Circulatory Shock.
Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs.
Surv Biopharma develops a drug discovery platform that facilitates research and development of veterinary drugs and pharmaceutical products.
Brise Pharma operates in the scientific research and technical service industry.
Vybio is a high-tech enterprise focusing on innovative drug research and development.
Chirality Biosciences is a developer of chiral molecule separation technology enabling faster, safer, and side-effect-free drug production.
Bexorg provides a technology platform for central nervous system drug discovery and development.
AeroRx Therapeutics is a biopharmaceutical company that developing proprietary, combination products.
OncoC4 is a biopharmaceutical company that engages in the discovery and development of novel biologicals for cancer treatment.
AusperBio is a biotechnology company that develops innovative drugs for curing chronic hepatitis B and other major infectious diseases.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.